KEFLIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEFLIN is a small-molecule injectable antibiotic approved in 1974 by Eli Lilly and Company. The drug's specific mechanism of action and therapeutic indications are not fully detailed in available data. It is administered via injection and represents a mature, legacy antibiotic product.
LOE Approaching
Product is in decline phase with approaching loss of exclusivity; expect contracting team size and reduced commercial investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KEFLIN offers limited career advancement opportunities given its LOE-approaching status and minimal job pipeline. Roles on this product focus on managed decline, compliance, and defending market share against generics rather than growth initiatives.
Brand ManagerSales Representative
Worked on KEFLIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.